LOGIN  |  REGISTER
Assertio
Terns Pharmaceuticals

electroCore to Participate in Upcoming Investor Conferences

September 26, 2024 | Last Trade: US$10.96 1.04 10.48

ROCKAWAY, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor events: 

  • October 17 -- Management will participate in a fireside chat with Anthony Vendetti, the Director of Research and Senior Healthcare Analyst, at the Maxim Virtual Healthcare Summit
  • October 29 - Management will participate in one-on-one meetings, and host a group presentation at the LD Micro Main Event XVII. This event will take place in Los Angeles, California and the company’s group presentation is scheduled for 4:30 p.m. PT.

Live webcasts and replays of group presentations will be made available on electroCore’s investor relations website at https://investor.electrocore.com/events-and-presentations.

Investors interested in scheduling a meeting with management at an upcoming event can contact FNK IR at This email address is being protected from spambots. You need JavaScript enabled to view it..

electroCore’s participation and schedule is subject to change.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB